Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

OTCID:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

(1566)
•••

Post by Duster340on May 07, 2025 11:00am

159 Views

Post# 36564313

Taro pharmaceutical

is based in brampton ontario a privatley held company. looks like dan landed on his feet elsewhere

https://www.taro.ca/

Dan Legault is COO at Juniper Genomics, a company developing proprietary genetic testing technology that dramatically reduces the time, cost and uncertainty of in-vitro fertilization (IVF) procedures. He is a board member of Neupath Health, a Canadian leader in the treatment of chronic pain.

https://www.junipergenomics.com/

<< Previous

Bullboard Posts

The disconnect in silver markets